Teleflex Incorporated (NYSE:TFX - Free Report) - Research analysts at Zacks Research lowered their FY2024 earnings per share (EPS) estimates for shares of Teleflex in a note issued to investors on Wednesday, January 8th. Zacks Research analyst R. Department now forecasts that the medical technology company will post earnings per share of $13.95 for the year, down from their prior forecast of $13.97. The consensus estimate for Teleflex's current full-year earnings is $13.98 per share. Zacks Research also issued estimates for Teleflex's Q1 2025 earnings at $3.51 EPS, Q1 2026 earnings at $4.14 EPS, Q2 2026 earnings at $4.16 EPS and Q3 2026 earnings at $4.13 EPS.
Teleflex (NYSE:TFX - Get Free Report) last posted its quarterly earnings results on Thursday, October 31st. The medical technology company reported $3.49 EPS for the quarter, topping analysts' consensus estimates of $3.38 by $0.11. Teleflex had a return on equity of 14.19% and a net margin of 7.85%. The business had revenue of $764.40 million during the quarter, compared to the consensus estimate of $768.68 million. During the same period last year, the firm earned $3.64 earnings per share. The company's revenue for the quarter was up 2.4% compared to the same quarter last year.
A number of other analysts have also recently weighed in on the stock. Needham & Company LLC reissued a "hold" rating on shares of Teleflex in a report on Monday, December 16th. Mizuho cut their target price on shares of Teleflex from $275.00 to $250.00 and set a "neutral" rating on the stock in a report on Friday, November 1st. Truist Financial lowered their target price on Teleflex from $227.00 to $200.00 and set a "hold" rating for the company in a report on Wednesday, December 18th. StockNews.com upgraded shares of Teleflex from a "hold" rating to a "buy" rating in a research report on Thursday, November 28th. Finally, Royal Bank of Canada cut their price target on Teleflex from $275.00 to $245.00 and set an "outperform" rating on the stock in a report on Friday, November 1st. Three analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $252.50.
Get Our Latest Analysis on Teleflex
Teleflex Stock Performance
Shares of TFX stock traded up $4.23 on Monday, hitting $178.84. 480,230 shares of the stock traded hands, compared to its average volume of 476,590. The company's fifty day moving average is $185.76 and its 200 day moving average is $216.38. Teleflex has a 1-year low of $171.69 and a 1-year high of $256.85. The company has a market capitalization of $8.31 billion, a PE ratio of 35.55, a PEG ratio of 1.84 and a beta of 1.16. The company has a debt-to-equity ratio of 0.37, a current ratio of 2.42 and a quick ratio of 1.39.
Institutional Trading of Teleflex
A number of large investors have recently added to or reduced their stakes in TFX. Cromwell Holdings LLC grew its position in Teleflex by 59.0% during the 3rd quarter. Cromwell Holdings LLC now owns 132 shares of the medical technology company's stock worth $33,000 after purchasing an additional 49 shares in the last quarter. Avior Wealth Management LLC increased its holdings in shares of Teleflex by 190.6% in the 3rd quarter. Avior Wealth Management LLC now owns 154 shares of the medical technology company's stock valued at $38,000 after purchasing an additional 101 shares during the period. Ashton Thomas Securities LLC acquired a new position in Teleflex in the 3rd quarter valued at approximately $40,000. True Wealth Design LLC lifted its position in Teleflex by 16,600.0% in the 3rd quarter. True Wealth Design LLC now owns 167 shares of the medical technology company's stock worth $41,000 after buying an additional 166 shares in the last quarter. Finally, Canada Pension Plan Investment Board acquired a new stake in shares of Teleflex during the 2nd quarter valued at $42,000. 95.62% of the stock is currently owned by institutional investors.
Teleflex Announces Dividend
The firm also recently declared a quarterly dividend, which was paid on Monday, December 16th. Shareholders of record on Friday, November 15th were issued a $0.34 dividend. This represents a $1.36 dividend on an annualized basis and a yield of 0.76%. The ex-dividend date was Friday, November 15th. Teleflex's payout ratio is 27.04%.
About Teleflex
(
Get Free Report)
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.
Read More
Before you consider Teleflex, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teleflex wasn't on the list.
While Teleflex currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
